Novozymes Short Interest Plummets in September
Novozymes A/S saw its short interest fall to 546 shares by Sept. 30, down 95.5% from 12,081 shares two weeks earlier. That represented essentially no shares sold short and a days-to-cover ratio near zero. The company recently reported quarterly EPS of $0.44, missing estimates, while revenue of $1.30 billion topped expectations; the stock traded at $65.26.
By late September, bearish positioning in Novozymes had nearly vanished: reported short positions dropped from 12,081 shares on Sept. 15 to 546 on Sept. 30, a 95.5% decrease. Against average daily trading of 47,865 shares, that left a days-to-cover measure near zero and a negligible share of the company’s stock held short.
Separately, Elefante Mark B lifted its second-quarter holding by 73.5%, finishing with 5,900 shares worth about $371,000. Novozymes, a Danish biotechnology company focused on enzyme and microbial solutions, posted quarterly EPS of $0.44 versus $0.60 expected, while revenue of $1.30 billion beat the $1.27 billion consensus. The stock closed at $65.26.
The near-zero short interest may suggest traders see limited near-term downside, potentially affecting investor sentiment and liquidity for NVZMY holders. Because the company supplies enzymes and microbial products used in food, agriculture, bioenergy, and manufacturing, its performance could influence customers and workers in those sectors. However, with only a handful of shares short, the signal may have little broader societal effect.